eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2007
vol. 32
 
Share:
Send email
Share:
abstract:


Review paper
CD20 as a target for therapy

Magdalena Winiarska
,
Jacek Bil
,
Urszula Demkow
,
Maria Wąsik

(Centr Eur J Immunol 2007; 32 (4): 239-246)
Online publish date: 2007/12/10
View full text Get citation
 
Rituximab is a chimeric human-mouse monoclonal antibody directed against CD20 antigen. CD20 antigen is characterisitc for precursors and mature B lymphocytes. Rituximab is thought to induce complement-mediated cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and apoptosis. Rituximab is mainly used to treat non-Hodgkin’s lymphomas, however it may prove an optimal treatment in various diseases related to autoantibody production. Beside rituximab there are other anti-CD20 antibodies: ibritumomab, tositumomab (both conjugated with radioisotopes), ofatumumab (human antibody undergoing clinical studies). The other strategies to target lymphoma cells include small peptides (mimotopes) that mimic CD20 antigen and thus force patient’s organism to produce anti-CD20 antibodies.
keywords:

rituximab, non-Hodgkin’s lymphoma, CD20 antigen, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.